Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [Grupo de Estudio de Linfoproliferativos de Latino América (GELL)]

References

• Globocan. Data source from international agency for research on cancer. 2020. Available from: http://gco.iarc.fr.
   Google Scholar
• Chihara D, Ito H, Matsuda T, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–45.
   PubMed Web of Science ®Google Scholar
• Perry AM, Jacque D, Nathwani BN, et al. Classification of non-Hodgkin lymphoma in seven geographic regions around the world: review of 4539 cases from the International non-Hodgkin lymphoma classification project, ASH abst#1484. Blood. 2015;126:1484 (abstr).
   Web of Science ®Google Scholar
• World Bank. World Bank country and lending groups. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.
   Google Scholar
• Tietsche de Moraes Hungria V, Chiattone C, Pavlovsky M, et al. Epidemiology of hematologic malignancies in real-world settings: findings from the Hemato-Oncology Latin America observational registry study. J Glob Oncol. 2019;5:1–19.
   PubMed Web of Science ®Google Scholar
• Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood. 2012;120:4795–801.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002–6.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010 Sep 23;116(12):2040–5.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.
   PubMed Web of Science ®Google Scholar
• Villela L, López-Guillermo A, Montoto S, et al. Prognostic features, and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer. 2001;91:1557–1562.
   PubMed Web of Science ®Google Scholar
• Rovira J, Valera A, Colomo L, et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol. 2015;94:803–812.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer J. 2021;11:68–78.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Asklid A, Eketorp Sylvan S, Mattsson A, et al. A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy. Leuk Lymphoma. 2020 Sep;61(9):2136–2144.
   PubMed Web of Science ®Google Scholar
• Sonnevi K, Wästerlid T, Melén CM, et al. Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study. Br J Haematol. 2021 Jan;192(1):75–81.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375–90.
   PubMed Web of Science ®Google Scholar
• Torres-Viera M, Beltran B, Villela L, et al. Follicular Lymphoma in Latin America: real-world experience from 763 patients. Blood. 2020;136(Supplement 1):12–13.
   Google Scholar
• Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13:140–147.
   PubMed Web of Science ®Google Scholar
• Brandt L, Kimby E, Nygren P, et al. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Acta Oncol. 2001;40:213–23.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Longo DL. Is watch and wait still acceptable for patients with low-grade follicular lymphoma? Blood. 2016;127:2804–2808.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516–22. Erratum in: J Clin Oncol. 2016; 34:1430.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
   Google Scholar
• Hernandez-Ruiz E, Alvarado-Ibarra M, Juan Lien-Chang LE, et al. Epidemiology and clinical characteristics of non-Hodgkin lymphoma in Mexico. World J Oncol. 2021;12:28–33.
   PubMedGoogle Scholar
• Schmitz N, de Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176:851–866.
   PubMed Web of Science ®Google Scholar
• Idrobo H, Beltrán BE, Villela L, et al. Serum albumin is an independent factor predicting survival in patients with peripheral T cell lymphoma: a multi-institutional study from the Latin American working group for lymphomas (GELL). Blood. 2019;134(Supplement_1):4047.
   Google Scholar
• Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood. 2011;117:3402–3408.
   PubMed Web of Science ®Google Scholar